Article: RIPK3-a predictive marker for personalized immunotherapy?

Cancer immunotherapy is an attractive therapeutic option but it is currently unclear which patient may benefit from such approaches. Using the model of cervical cancer, we have demonstrated that PolyIC-driven immunogenicity strictly depends on the necroptosis regulator RIPK3 in the neoplastic cells. This proposes RIPK3 as a novel predictive marker for personalization of cancer immunotherapy.

Citing Articles

Human Papillomavirus Carcinogenicity and the Need of New Perspectives: Thoughts from a Retrospective Analysis on Human Papillomavirus Outcomes Conducted at the Hospital University of Bari, Apulia, Italy, between 2011 and 2022.

Del Prete R, Nesta D, Triggiano F, Lorusso M, Garzone S, Vitulano L Diagnostics (Basel). 2024; 14(9).

PMID: 38732382 PMC: 11083870. DOI: 10.3390/diagnostics14090968.

Immune infiltration and a necroptosis-related gene signature for predicting the prognosis of patients with cervical cancer.

Xing X, Tian Y, Jin X Front Genet. 2023; 13:1061107.

PMID: 36685937 PMC: 9852722. DOI: 10.3389/fgene.2022.1061107.

A comprehensive pan-cancer analysis of necroptosis molecules in four gynecologic cancers.

Zheng J, Cai X, Zhang Y, Wang H, Liu L, Tang F BMC Cancer. 2022; 22(1):1160.

PMID: 36357839 PMC: 9650890. DOI: 10.1186/s12885-022-10166-6.

The Creation of the Suppressive Cancer Microenvironment in Patients with HPV-Positive Cervical Cancer.

Chaberek K, Mrowiec M, Kaczmarek M, Dutsch-Wicherek M Diagnostics (Basel). 2022; 12(8).

PMID: 36010256 PMC: 9406692. DOI: 10.3390/diagnostics12081906.

Necroptosis in Immuno-Oncology and Cancer Immunotherapy.

Sprooten J, De Wijngaert P, Vanmeerbeerk I, Martin S, Vangheluwe P, Schlenner S Cells. 2020; 9(8).

PMID: 32752206 PMC: 7464343. DOI: 10.3390/cells9081823.

References

1.

Pahne-Zeppenfeld J, Schroer N, Walch-Ruckheim B, Oldak M, Gorter A, Hegde S . Cervical cancer cell-derived interleukin-6 impairs CCR7-dependent migration of MMP-9-expressing dendritic cells. Int J Cancer. 2013; 134(9):2061-73. DOI: 10.1002/ijc.28549. View

2.

Sun L, Wang H, Wang Z, He S, Chen S, Liao D . Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012; 148(1-2):213-27. DOI: 10.1016/j.cell.2011.11.031. View

3.

Glavan T, Pavelic J . The exploitation of Toll-like receptor 3 signaling in cancer therapy. Curr Pharm Des. 2014; 20(42):6555-64. DOI: 10.2174/1381612820666140826153347. View

4.

Karim R, Meyers C, Backendorf C, Ludigs K, Offringa R, van Ommen G . Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One. 2011; 6(3):e17848. PMC: 3056770. DOI: 10.1371/journal.pone.0017848. View

5.

Altenburg A, Baldus S, Smola H, Pfister H, Hess S . CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma. J Immunol. 1999; 162(7):4140-7. View

RIPK3-a Predictive Marker for Personalized Immunotherapy?